Altimmune (ALT) Competitor Comparison
We are evaluating the key criteria listed to compare Altimmune (ALT) against its competitors in the Biotechnology industry.
Market Capitalization
144 / 368Gross Profits
216 / 278Total Revenue
266 / 300EBITDA
0 / 337Free Cashflow
220 / 352Quick Ratio
62 / 357Earnings per Share
186 / 359Dividend yield
0 / 6Total Cash
190 / 358Performance 3 years
111 / 368Performance 5 years
21 / 368Performance 10 years
264 / 368Linearity 3 years
22 / 368Linearity 5 years
225 / 368Linearity 10 years
312 / 367Total Rank
103 / 368Dividend Rank
345 / 368Valuation Rank
330 / 368Piotroski Rank
73 / 368Muliplier Rank
263 / 368Market Capitalization - ALT ranking 144 / 368
Obligatory risk notice
We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.